Cadrenal Therapeutics, Inc. (Nasdaq:CVKD)
Health Care/Life Sciences • Pharmaceuticals
CIK 1937993
Company
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Address
822 A1A North
Suite 306
Ponte Vedra Beach, Florida 32082
822 A1A North
Suite 306
Ponte Vedra Beach, Florida 32082
Employees
4
4
Stock Info
Key Executives
Board Of Directors
Chairman & Chief Executive Officer Quang X. Pham |
Independent Director Robert Lisicki |
Independent Director John R. Murphy |
Independent Director Steven L. Zelenkofske |
Independent Director Glynn Wilson |
SEC filings
Date | Form | Event |
---|---|---|
20 Dec, 2024 | 424B5 | |
25 Nov, 2024 | 424B3 | |
22 Nov, 2024 | EFFECT | |
14 Nov, 2024 | S-3 | |
14 Nov, 2024 | D | |
14 Nov, 2024 | SC 13G/A | |
7 Nov, 2024 | 10-Q | |
7 Nov, 2024 | 8-K | |
4 Nov, 2024 | 8-K | |
4 Nov, 2024 | 424B5 | |
24 Oct, 2024 | 8-K | |
4 Oct, 2024 | SC 13G | |
25 Sep, 2024 | 8-K | |
5 Sep, 2024 | 8-K | |
20 Aug, 2024 | 8-K | |
16 Aug, 2024 | 8-K | |
8 Aug, 2024 | 8-K | |
7 Aug, 2024 | 10-Q | |
6 Aug, 2024 | 8-K | |
31 Jul, 2024 | 8-K | |
12 Jun, 2024 | DEFA14A | |
11 Jun, 2024 | DEF 14A | |
11 Jun, 2024 | ARS | |
29 May, 2024 | PRE 14A | |
9 May, 2024 | 10-Q | |
9 May, 2024 | 8-K | |
10 Apr, 2024 | 4 | |
9 Apr, 2024 | 8-K | |
3 Apr, 2024 | 3 | |
3 Apr, 2024 | 4 | |
2 Apr, 2024 | POS AM | |
2 Apr, 2024 | EFFECT | |
20 Mar, 2024 | EFFECT | |
18 Mar, 2024 | CORRESP | |
15 Mar, 2024 | UPLOAD | |
12 Mar, 2024 | S-3 | |
12 Mar, 2024 | S-8 | |
12 Mar, 2024 | 8-K | |
11 Mar, 2024 | 10-K | |
11 Mar, 2024 | 8-K | |
5 Mar, 2024 | 8-K | |
15 Feb, 2024 | 8-K/A | |
14 Feb, 2024 | SC 13G | |
13 Feb, 2024 | SC 13G/A | |
12 Feb, 2024 | 4 | |
12 Feb, 2024 | SC 13G | |
12 Feb, 2024 | 8-K | |
9 Nov, 2023 | 8-K | |
9 Nov, 2023 | 10-Q | |
23 Oct, 2023 | 8-K | |
6 Oct, 2023 | 4 | |
8 Sep, 2023 | 8-K | |
6 Sep, 2023 | 4 | |
5 Sep, 2023 | 4 | |
31 Aug, 2023 | DEFA14A | |
31 Aug, 2023 | DEFA14A | |
28 Aug, 2023 | ARS | |
28 Aug, 2023 | DEF 14A | |
18 Aug, 2023 | 8-K | |
16 Aug, 2023 | 8-K | |
16 Aug, 2023 | 424B3 | |
10 Aug, 2023 | 8-K | |
10 Aug, 2023 | 10-Q | |
1 Aug, 2023 | 424B3 | |
28 Jul, 2023 | EFFECT | |
26 Jul, 2023 | CORRESP | |
26 Jul, 2023 | UPLOAD | |
24 Jul, 2023 | 4 | |
24 Jul, 2023 | 8-K | |
24 Jul, 2023 | 3 | |
24 Jul, 2023 | S-1 | |
18 Jul, 2023 | D | |
26 May, 2023 | 8-K | |
10 May, 2023 | 10-Q | |
10 May, 2023 | 8-K | |
31 Mar, 2023 | 3/A | |
30 Mar, 2023 | 10-K | |
27 Mar, 2023 | 8-K | |
27 Mar, 2023 | SC 13G | |
22 Mar, 2023 | 4 | |
16 Mar, 2023 | 4 | |
13 Feb, 2023 | 4 | |
25 Jan, 2023 | 8-K | |
24 Jan, 2023 | 4 | |
24 Jan, 2023 | S-8 | |
24 Jan, 2023 | 4 | |
24 Jan, 2023 | 4 | |
23 Jan, 2023 | 424B4 | IPO completed |
23 Jan, 2023 | 424B4 | |
20 Jan, 2023 | SEC STAFF | |
20 Jan, 2023 | CERT | |
19 Jan, 2023 | 3 | |
19 Jan, 2023 | 3 | |
19 Jan, 2023 | EFFECT | |
19 Jan, 2023 | 3 | |
19 Jan, 2023 | 3 | |
19 Jan, 2023 | 3 | |
19 Jan, 2023 | 3 | |
17 Jan, 2023 | CORRESP | |
17 Jan, 2023 | CORRESP | |
17 Jan, 2023 | S-1/A | |
17 Jan, 2023 | 8-A12B | |
28 Dec, 2022 | S-1/A | |
8 Dec, 2022 | S-1/A | |
8 Dec, 2022 | UPLOAD | |
8 Dec, 2022 | D | |
8 Dec, 2022 | CORRESP | |
6 Dec, 2022 | S-1/A | |
17 Oct, 2022 | CORRESP | |
17 Oct, 2022 | S-1/A | |
13 Oct, 2022 | UPLOAD | |
12 Oct, 2022 | SEC STAFF | |
11 Oct, 2022 | S-1/A | |
22 Sep, 2022 | S-1 | |
22 Sep, 2022 | CORRESP | |
2 Sep, 2022 | DRS/A | |
2 Sep, 2022 | DRSLTR | |
30 Aug, 2022 | UPLOAD | |
23 Aug, 2022 | DRSLTR | |
23 Aug, 2022 | DRS/A | |
11 Aug, 2022 | UPLOAD | |
25 Jul, 2022 | D | |
15 Jul, 2022 | DRS |
Last update:2025-03-06 12:38:34.079509
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.